These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 14713514)

  • 1. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversity of signaling underlying responses mediated by selective activation of the platelet thromboxane A2 (TXA2) receptor; pharmacological and kinetic studies in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003 Sep; 14(6):359-74. PubMed ID: 14602550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.
    Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM
    Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent responses elicited by isolated activation of platelet Gq-coupled receptors, in vitro: a novel approach for their separation and analysis.
    Maayani S; Patel ND; Craddock-Royal BD; Schwarz TE; Tagliente TM
    Platelets; 2003 Mar; 14(2):89-102. PubMed ID: 12745451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
    Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R
    Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.
    Hardy AR; Hill DJ; Poole AW
    Platelets; 2005 Nov; 16(7):415-29. PubMed ID: 16236603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
    Storey RF; May JA; Heptinstall S
    Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation.
    Eckly A; Gendrault JL; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2001 Apr; 85(4):694-701. PubMed ID: 11341507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
    Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2 receptors in platelet function.
    Hechler B; Cattaneo M; Gachet C
    Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
    Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
    Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
    Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M
    Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways.
    Garcia A; Kim S; Bhavaraju K; Schoenwaelder SM; Kunapuli SP
    Biochem J; 2010 Jul; 429(2):369-77. PubMed ID: 20441566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
    Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S
    Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.
    Jantzen HM; Gousset L; Bhaskar V; Vincent D; Tai A; Reynolds EE; Conley PB
    Thromb Haemost; 1999 Jan; 81(1):111-7. PubMed ID: 10348701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes.
    Maayani S; Tagliente TM; Schwarz T; Martinelli G; Martinez R; Shore-Lesserson L
    Platelets; 2001 Mar; 12(2):83-93. PubMed ID: 11297036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets.
    Mateos-Trigos G; Evans RJ; Heath MF
    Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
    Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
    Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.
    Fabre JE; Nguyen M; Latour A; Keifer JA; Audoly LP; Coffman TM; Koller BH
    Nat Med; 1999 Oct; 5(10):1199-202. PubMed ID: 10502826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.